T Cell Therapy Pipeline Insight Report 2024

Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "T cell therapy - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering.

The report covers comprehensive insights of present clinical development scenario and growth prospects across the T cell therapy market. A detailed picture of the T cell therapy pipeline landscape is provided, which includes the disease overview and T cell therapy treatment guidelines. The assessment part of the report embraces in-depth T cell therapy commercial assessment and clinical assessment of the T cell therapy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T cell therapy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of T cell therapy with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the T cell therapy treatment.
  • T cell therapy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of T cell therapy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

In-depth T cell therapy Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

T cell therapy Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.

Scope of the Report

  • The T cell therapy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for T cell therapy across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of T cell therapy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed T cell therapy research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across T cell therapy.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for T cell therapy.
  • In the coming years, the T cell therapy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence T cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the T cell therapy treatment market. Several potential therapies for T cell therapy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the T cell therapy market size in the coming years.
  • This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of T cell therapy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

  • What are the current options for T cell therapy treatment?
  • How many companies are developing therapies for the treatment of T cell therapy?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of T cell therapy?
  • How many T cell therapy emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of T cell therapy?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact T cell therapy market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of T cell therapy?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing T cell therapy therapies?
  • What are the clinical studies going on for T cell therapy and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for T cell therapy?
  • How many patents are granted and pending for the emerging therapies for the treatment of T cell therapy?

Key Topics Covered:

1. Report Introduction

2. T cell therapy
2.1. Overview
2.2. History
2.3. T cell therapy Symptoms
2.4. Causes
2.5. Pathophysiology
2.6. T cell therapy Diagnosis
2.6.1. Diagnostic Guidelines

3. T cell therapy Current Treatment Patterns
3.1. T cell therapy Treatment Guidelines

4. T cell therapy - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. T cell therapy companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary
4.1.2. T cell therapy Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis T cell therapy Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.3. Assessment by Route of Administration
5.1.4. Assessment by Molecule Type
5.1.5. Assessment by MOA
5.1.6. Assessment by Target

6. T cell therapy Late Stage Products (Phase-III)

7. T cell therapy Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. T cell therapy Discontinued Products

13. T cell therapy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description Product Overview Mechanism of action
13.1.2. Research and Development Clinical Studies
13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail
13.1.4. Tabulated Product Summary

14. T cell therapy Key Companies

15. T cell therapy Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.2. Discontinued Products

17. T cell therapy Unmet Needs

18. T cell therapy Future Perspectives

19. T cell therapy Analyst Review

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/iv45bd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data